Results 61 to 70 of about 489,406 (280)
Mathematical Modeling of BCG-based Bladder Cancer Treatment Using Socio-Demographics [PDF]
arXiv, 2023 Cancer is one of the most widespread diseases around the world with millions of new patients each year. Bladder cancer is one of the most prevalent types of cancer affecting all individuals alike with no obvious prototypical patient. The current standard treatment for BC follows a routine weekly Bacillus Calmette-Guerin (BCG) immunotherapy-based ...
arxiv
Biomarker ResearchBackground and aims Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA. However, it is not clear which type of
Naheema S. Gordon +14 more
doaj +1 more source
Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer
Frontiers in Oncology, 2021 BackgroundBladder cancer is the 10th most common cancer and most common urothelial malignancy worldwide. Prognostic biomarkers for bladder cancer patients are required for individualized treatment. Monocarboxylate transporter 4 (MCT4), encoded by SLC16A3
Yang Zhao +7 more
doaj +1 more source
Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study [PDF]
, 2014 Background: There is evidence that cancer survivors are at increased risk of second primary cancers. Changes in the prevalence of risk factors and diagnostic techniques may have affected more recent risks.<p></p> Methods: We examined the
A Chopra +43 more
core +3 more sources
Evaluation of MMP‑2, MMP‑9, TIMP‑1, TIMP‑2, NGAL and MMP‑9/NGAL complex in urine and sera from patients with bladder cancer [PDF]
, 2015 The identification of biomarkers in urine or serum samples from patients with bladder cancer is urgently required for the development of non-invasive methods for the diagnosis of bladder carcinoma and to facilitate follow-up surveillance, to combat the ...
Bruzzese, Dario +2 more
core +1 more source
European Urology Open Science, 2023 Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary ...
Irene J. Beijert +28 more
doaj
ESMO Open, 2019 The Central European Cooperative Oncology Group (CECOG) and ‘ESMO Open—Cancer Horizons’ roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement or ...
Nils Wilking +7 more
doaj +1 more source
A general two-stage progressive model of cancer natural history to project downstaging due to multi-cancer screening tests [PDF]
arXiv, 2023 Multi-cancer early detection (MCED) tests offer to screen for multiple types of cancer with a single blood sample. Despite their promising diagnostic performance, evidence regarding their population benefit is not yet available. Expecting that benefit will derive from detecting cancer before it progresses to an advanced stage, we develop a general two ...
arxiv
Cancer Cell, 2004 Supported by NIH Specialized Programs of Research Excellence Grant in Genitourinary Cancer CA91846, and National Cancer Institute Grants CA16672, CA066723, and CA85078.
Anita L. Sabichi +12 more
openaire +3 more sources
Diagnostics, 2023 Bladder cancer is a common urological cancer and has the highest recurrence rate of any cancer. The aim of our study was to profile and characterize the protein expression of homeobox A13 (HOXA13) and homeobox B13 (HOXB13) genes in Malaysian bladder ...
Fee-Wai Chin +8 more
doaj +1 more source